Share the post "Zydus Lifesciences : Q4 2024 Financial Quarterly Report : YoY Sales Up 10.44 %, QoQ Up 22.83 %"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 10.44 % in the past year, substantial increase in net sales/revenue by 22.83 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 272.78 %. Marginal increase in other income during this quarter, up by 52.46%.
- Profit over the Year and quarter: Significant improvement in profitability for Zydus Lifesciences Limited. Notable increase of 247.88 % in net profit Year to Year, Zydus Lifesciences Limited’s profitability increased by 57.75 % in this quarter.
- EPS over the Year and quarter: EPS increased by 298.98 % Year to Year. EPS increased by 49.87 % in previous quarter. Positive impact on shareholders.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 5010.6 Cr | Rs. 4505.2 Cr | Rs. 5533.8 Cr | + 22.83 % | + 10.44 % |
Expenses | Rs. 3755 Cr | Rs. 3402.8 Cr | Rs. 3903.3 Cr | + 14.71 % | + 3.95 % |
Operating Profit | Rs. 1255.6 Cr | Rs. 1102.4 Cr | Rs. 1630.5 Cr | + 47.9 % | + 29.86 % |
OPM % | 25.06 % | 24.47 % | 29.46 % | + 4.99 % | + 4.4 % |
Other Income | Rs. 47.4 Cr | Rs. 115.9 Cr | Rs. 176.7 Cr | + 52.46 % | + 272.78 % |
Interest | Rs. 27.7 Cr | Rs. 19.8 Cr | Rs. 34.6 Cr | + 74.75 % | + 24.91 % |
Depreciation | Rs. 178.6 Cr | Rs. 194.8 Cr | Rs. 205.3 Cr | + 5.39 % | + 14.95 % |
Profit before tax | Rs. 1096.7 Cr | Rs. 1003.7 Cr | Rs. 1567.3 Cr | + 56.15 % | + 42.91 % |
Tax % | 28.24 % | 23.1 % | 20.76 % | -2.34 % | -7.48 % |
Net Profit | Rs. 358.2 Cr | Rs. 789.9 Cr | Rs. 1246.1 Cr | + 57.75 % | + 247.88 % |
EPS in Rs | Rs. 2.95 | Rs. 7.59 | Rs. 11.66 | + 53.62 % | + 295.25 % |
Today, we’re looking at Zydus Lifesciences Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 10.44 %. However, it did see a marginal increase of 22.83 % from the previous quarter. Expenses ticked up slightly by 14.71 % quarter-on-quarter, aligning with the annual rise of 3.95 %. Operating profit, while up 29.86 % compared to last year, faced a quarter-on-quarter increase of 47.9 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 4.4 %, but an expansion of 4.99 % sequentially. Other income rose by 52.46 % compared to the last quarter, despite an annual growth of 272.78 %. Interest expenses surged remarkably by 74.75 % from the previous quarter, yet the year-over-year increase remains at a moderate 24.91 %. Depreciation costs climbed by 5.39 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 14.95 %. Profit before tax grew annually by 42.91 % but saw an increase from the preceding quarter by 56.15 %.
Tax expenses as a percentage of profits decreased slightly by -7.48 % compared to last year, with a more notable quarter-on-quarter decrease of -2.34 %. Net profit rose by 247.88 % year-on-year but experienced a 57.75 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 295.25 % but a quarterly rise of 53.62 %. In summary, Zydus Lifesciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 5010.6 Cr | Rs. 4505.2 Cr | Rs. 5533.8 Cr | + 22.83 % | + 10.44 % |
Expenses | Rs. 3755 Cr | Rs. 3402.8 Cr | Rs. 3903.3 Cr | + 14.71 % | + 3.95 % |
Operating Profit | Rs. 1255.6 Cr | Rs. 1102.4 Cr | Rs. 1630.5 Cr | + 47.9 % | + 29.86 % |
Net Profit | Rs. 358.2 Cr | Rs. 789.9 Cr | Rs. 1246.1 Cr | + 57.75 % | + 247.88 % |
EPS in Rs | Rs. 2.95 | Rs. 7.59 | Rs. 11.66 | + 53.62 % | + 295.25 % |
In reviewing Zydus Lifesciences Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 10.44 % year-on-year growth, however, there was a minor increase of 22.83 % from the previous quarter. Expenses rose by 3.95 % compared to the previous year, with a 14.71 % increase quarter-on-quarter. Operating Profit surged by 29.86 % annually, and saw a 47.9 % increase from the last quarter.
Net Profit showed yearly increase of 247.88 %, and experienced a 57.75 % increase from the previous quarter. Earnings Per Share (EPS) rose by 295.25 % annually, however rose by 53.62 % compared to the last quarter. In essence, while Zydus Lifesciences Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.